Site is Being Upgraded

Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 30/December/2017, 10.56 pm

Lifespan extension therapy: Acacedin, isolated from Damiana, among others, prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 29/December/2017, 11.41 pm
December 29, 2017
Vitamin B-based therapy for TIIDM and obesity-associated metabolic deficits: A therapeutic mix (PMFA) encompassing Pyridoxamine (PM) and Folic acid (FA) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 30/December/2017, 11.21 pm
December 30, 2017
Show all

Introduction: What they say

A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, California, USA; and Koch Institute at MIT, 500 Main Street, Cambridge, USA shows that “Fasting-Mimicking Diet Promotes Ngn3-Driven ß-Cell Regeneration to Reverse Diabetes.” This research paper was published, in the 23 February 2017 issue of the journal “Cell” [One of the best research journals in Biology with an I.F of 28 plus], by  Prof. and Director of Longevity institute Valter Longo, Cheng CW and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene  [easy_payment currency=”USD”]

Price 1, 500


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

It has recently been shown that fasting mimicking diet (FMD):(1) increases the expression of Sox17, Pdx-1 (Pancreatic And Duodenal Homeobox 1), & Ngn3 (Neurogenin-3) sequentially; (2) promotes regeneration of insulin-producing ß cells; (3) decreases PKA (Protein Kinase A) and mTOR activity; (4) increases reprogramming proteins Sox2 and Ngn3 expression; (5) increases insulin secretion; and (6) promotes glucose homeostasis, suggesting that FMD: (i) promotes reprogramming of pancreatic cells to restore insulin secretion in islets; and (ii) can reverse both T1D and T2D.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based regenerative therapy for T1D and TIID.

A pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB), by increasing the expression of its target genes, it may increase the expression of Sox17, Ngn3, Sox2, Pdx-1, NKX6.1, Pax6, INS etc. (Fig. 1). Thereby, it may: (1) decrease the expression of mTOR;  (2) increase generation of insulin-producing ß cells; (3) increase insulin secretion; and (4) promote glucose homeostasis, suggesting that LALB–may replace the need for FMD or function as an effective alternative to FMD–may find its use in clinic in attenuating and/or reversing both T1D and T2D, as it turns on most of the reprogramming/insulin-producing genes turned by the FMD (Fig.1).

Figure 1. Mechanistic insights into how a pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB), by turning on the expression of Ngn3, NKX6.1, Pax6, and INS among others genes, may promote reprogramming of pancreatic cells to restore insulin secretion in islets; and reverse both T1D and T2D.

Figure 2. The chemical structure of Luteolin, Apigenin and Loureirin B (LAL) and the source from which they can be derived is indicated above.

Thus, pharmacological formulations encompassing “Luteolin, Apigenin and Loureirin B (LALB) or their analogues, either alone or in combination with other drugs/natural substances/compounds” may be used to treat and cure T1D and T2D.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does a pharmaceutical mixture encompassing  Luteolin, Apigenin and Loureirin B (LALB) increase the expression of Sox17, Sox2, Pdx-1, and Ngn3 to reprogram of pancreatic cells, and to restore insulin secretion?

Amount: $ 1, 500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 30/December/2017, 10.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.